All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
At the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Gail Roboz, Weill Cornell Medicine, New York, US, shared her insights with the AML Hub. We asked “What exciting updates on maintenance therapy in acute myeloid leukemia were presented at ASH 2023?”
What exciting updates on maintenance therapy in acute myeloid leukemia were presented at ASH 2023?
Roboz discusses the use of oral azacitidine as a maintenance therapy for patients with acute myeloid leukemia, highlighting results from the QUAZAR AML-001 trial, before exploring the impact of maintenance therapy on measurable residual disease status and postremission outcomes. She reviews the optimal selection of maintenance therapies, and how measurable residual disease status can influence treatment decisions in subgroups such as NPM1-mutated and FLT3-mutated AML. Roboz concludes by emphasizing the need for more randomized clinical trials evaluating maintenance therapies and considers future directions, including menin inhibitors and high-sensitivity measurable residual disease testing.
AML World Awareness Day 2020 | Clinical trials involving novel agents in AML
On April 21, 2020, communities will unite on Acute Myeloid Leukemia (AML) World Awareness Day (WAD) to raise awareness of AML. Both scientific and patient communities will...
Phase III QUAZAR AML-001 trial results
A summary of the QUAZAR AML-001 trial, as presented by Andrew Wei, The Alfred Hospital, Melbourne, AU, at the 61st ASH meeting in Orlando, US.
Subscribe to get the best content related to AML delivered to your inbox